Platelet Indices Altered in Severe Malaria
|
By LabMedica International staff writers Posted on 08 Jan 2014 |

Image: Photomicrograph shows a growing Plasmodium vivax trophozoite in a blood smear (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Changes in platelet counts during acute malaria are common and such changes are a major cause of concern to clinicians because such cases are more likely to evolve into serious and complicated disease.
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
Latest Hematology News
- New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
- New Automated Hemostasis Systems Become Available Across US Laboratories
- Updated Ferritin Thresholds Improve Detection of Iron Deficiency
- Variation in AML Residual Disease Testing Prompts Push for Standardization
- Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
- Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
- Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreMolecular Diagnostics
view channel
Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease
Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more
Genomic Test Guides Extended Endocrine Therapy in Early Breast Cancer
Adjuvant endocrine therapy is standard for hormone receptor–positive early breast cancer, yet prolonged treatment brings side effects and adherence problems. Whether to continue beyond five years is a... Read moreImmunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read moreMicrobiology
view channel
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
Bleeding after menopause requires prompt investigation for uterine cancer, although most women who undergo testing do not have the disease. In the U.K., uterine cancer affects nearly 10,000 women each... Read more
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read moreTechnology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







